Diabetes & Endocrinologydiabeteshyperglycemia
Teprotumumab for Thyroid Eye Disease Carries a Measurable Long-Term Dysglycemia Risk
By MedXY|May 3, 2026
A large multinational cohort study found that teprotumumab use in thyroid eye disease was associated with higher risks of prediabetes, diabetes, and antidiabetes medication initiation over 5 years.